Difference between revisions of "Endometrial cancer - null regimens"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "|Phase III (" to "|Phase 3 (")
Line 20: Line 20:
 
|[http://clincancerres.aacrjournals.org/content/25/8/2424 Kitson et al. 2018 (PREMIUM)]
 
|[http://clincancerres.aacrjournals.org/content/25/8/2424 Kitson et al. 2018 (PREMIUM)]
 
|2015-2017
 
|2015-2017
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|Metformin
 
|Metformin
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of posttreatment IHC expression of Ki-67
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of posttreatment IHC expression of Ki-67
Line 49: Line 49:
 
|[https://doi.org/10.1200/JCO.1985.3.9.1240 Omura et al. 1985 (GOG 20)]
 
|[https://doi.org/10.1200/JCO.1985.3.9.1240 Omura et al. 1985 (GOG 20)]
 
|1973-1982
 
|1973-1982
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|Doxorubicin
 
|Doxorubicin
 
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
 
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
Line 55: Line 55:
 
|[https://www.gynecologiconcology-online.net/article/S0090-8258(03)00863-1/fulltext Keys et al. 2004 (GOG 99)]
 
|[https://www.gynecologiconcology-online.net/article/S0090-8258(03)00863-1/fulltext Keys et al. 2004 (GOG 99)]
 
|1987-1995
 
|1987-1995
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Endometrial_cancer#Radiation_therapy|RT]]
 
|[[Endometrial_cancer#Radiation_therapy|RT]]
 
| style="background-color:#d73027" |Inferior RFS
 
| style="background-color:#d73027" |Inferior RFS
Line 61: Line 61:
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552301/ Hogberg et al. 2010 (EORTC 55991)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552301/ Hogberg et al. 2010 (EORTC 55991)]
 
|1996-2007
 
|1996-2007
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|1. [[Endometrial_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]]<br> 2. Cisplatin & Epirubicin<br> 3. Epirubicin & Paclitaxel<br> 4. Carboplatin & Doxorubicin<br> 5. [[Endometrial_cancer#Carboplatin_.26_Paclitaxel_.28CP.29|Carboplatin & Paclitaxel]]
 
|1. [[Endometrial_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]]<br> 2. Cisplatin & Epirubicin<br> 3. Epirubicin & Paclitaxel<br> 4. Carboplatin & Doxorubicin<br> 5. [[Endometrial_cancer#Carboplatin_.26_Paclitaxel_.28CP.29|Carboplatin & Paclitaxel]]
 
| style="background-color:#fc8d59" |Seems to have inferior PFS
 
| style="background-color:#fc8d59" |Seems to have inferior PFS
Line 67: Line 67:
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552301/ Hogberg et al. 2010 (MaNGO ILIADE-III)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552301/ Hogberg et al. 2010 (MaNGO ILIADE-III)]
 
|1998-2007
 
|1998-2007
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Endometrial_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]]
 
|[[Endometrial_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
Line 98: Line 98:
 
|[https://doi.org/10.1200/jco.2005.02.8464 Barakat et al. 2006 (GOG 137A)]
 
|[https://doi.org/10.1200/jco.2005.02.8464 Barakat et al. 2006 (GOG 137A)]
 
|1997-2003
 
|1997-2003
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|Estrogen replacement therapy
 
|Estrogen replacement therapy
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
Line 127: Line 127:
 
|(DUO-E)
 
|(DUO-E)
 
|2020-ongoing
 
|2020-ongoing
−
|style="background-color:#1a9851"|Phase III (C)
+
|style="background-color:#1a9851"|Phase 3 (C)
 
|1. Durvalumab<br> 2. Durvalumab & Olaparib
 
|1. Durvalumab<br> 2. Durvalumab & Olaparib
 
| style="background-color:#d3d3d3" |In progress
 
| style="background-color:#d3d3d3" |In progress

Revision as of 14:54, 12 February 2022

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main endometrial cancer page for current regimens.


Neoadjuvant therapy

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kitson et al. 2018 (PREMIUM) 2015-2017 Phase 3 (C) Metformin Did not meet primary endpoint of posttreatment IHC expression of Ki-67

No active antineoplastic treatment prior to surgery.

Subsequent treatment

References

  1. PREMIUM: Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. Epub 2018 Dec 18. link to original article PubMed ISRCTN88589234

Adjuvant therapy

Observation

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Omura et al. 1985 (GOG 20) 1973-1982 Phase 3 (C) Doxorubicin Did not meet efficacy endpoints
Keys et al. 2004 (GOG 99) 1987-1995 Phase 3 (C) RT Inferior RFS
Hogberg et al. 2010 (EORTC 55991) 1996-2007 Phase 3 (C) 1. Cisplatin & Doxorubicin
2. Cisplatin & Epirubicin
3. Epirubicin & Paclitaxel
4. Carboplatin & Doxorubicin
5. Carboplatin & Paclitaxel 		Seems to have inferior PFS
Hogberg et al. 2010 (MaNGO ILIADE-III) 1998-2007 Phase 3 (C) Cisplatin & Doxorubicin Did not meet primary endpoint of PFS

No further treatment.

Preceding treatment

Subsequent treatment

  • MaNGO ILIADE-III: RT

References

  1. GOG 20: Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Sep;3(9):1240-5. link to original article PubMed
  2. GOG 99: Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. Erratum in: Gynecol Oncol. 2004 Jul;94(1):241-2. link to original article PubMed
  3. EORTC 55991/MaNGO ILIADE-III: Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422-31. Epub 2010 Jul 7. link to original article link to PMC article PubMed NCT00005583

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Barakat et al. 2006 (GOG 137A) 1997-2003 Phase 3 (C) Estrogen replacement therapy Did not meet primary endpoint of RFS

No active antineoplastic treatment. Note that this trial was stopped early due to the increased risk of ERT in the Women's Health Initiative trial, and should be considered inconclusive.

Preceding treatment

References

  1. GOG 137A: Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. link to original article PubMed NCT00002976
  2. SIENDO: NCT03555422

Maintenance after first-line therapy

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
(DUO-E) 2020-ongoing Phase 3 (C) 1. Durvalumab
2. Durvalumab & Olaparib 		In progress

Preceding treatment

  • Platinum-based chemotherapy

References

  1. DUO-E: NCT04269200
Retrieved from "https://hemonc.org/w/index.php?title=Endometrial_cancer_-_null_regimens&oldid=54542"